Nutratech Contests Press Surrounding New Bitter Orange Study

Nutratech Contests Press Surrounding New Bitter Orange Study

WAYNE, N.J.Nutratech issued arebuttal in response to new research on the effects of the bitter orangecompound synephrine on blood pressure and heart rate. According to Nutratech,negative publicity surrounding the study, which was published in the the AmericanJournal of Medicine (118, 9:998- 1003, 2005), may havemisled journalists.

The randomized, double blind, placebo-controlled, three-armcrossover study, led by Christine Haller, M.D., compared physiological effectsof two supplements marketed for weight lossXenadrine EFX, a multi-componentformulation containing synephrine as well as caffeine and other stimulants, andNutratechs Advantra Z®, formulated with 46.9 mg synephrine.

Xenadrine EFX but not Advantra Z increased systolic anddiastolic blood pressure within two hours of administration. The researchersattributed Xenadrine EFXs effects on blood pressure and heart rate tocaffeine and other stimulants in the multi-component formulation and noted aneightfold higher dose of synephrine had no effect on blood pressure. However, apress release dispatched by the University of California, San Francisco, put adifferent spin on study results, with a blatantly misleading headline and unsubstantiated claims of harmful health effectsattributed to Advantra Z, according to Nutratech.

Bob Green, president of Nutratech, said, While wewholeheartedly concur with Dr. Hallers recommendation that consumersparticularlythose with hypertension, heart disease or other pre-existing conditionsconsultwith their health care providers before embarking on any dietary supplementregimen, we also ask that they report their findings in a fair manner withoutheadline-grabbing and misleading hype.

For more information, visit www.nutratechinc.com or Booth#5124 at SupplySide West.